Insufficient Oxygenation in Septic Patients (INOX-SEPSIS)

• ClinicalTrials.gov Identifier: NCT03842722
• Recruitment Status: Recruiting
• First Posted: February 15, 2019
• Last Update Posted: March 30, 2021
• Sponsor: Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
• Information provided by (Responsible Party): Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

Study Description

Brief Summary:

This study will describe the change of mitochondrial oxygen tension (mitoPO2) compared to traditional parameters of oxygenation and oxygen balance in the first 24 hours of septic patients admitted to the intensive care unit of an academic hospital. The mitoPO2 will be measured on prespecified measurement moments in the ICU. With each measurement moment, arterial and central venous blood gasses will be taken too.

Condition or disease	Intervention/treatment
Sepsis; Critical Care; Mitochondria; Oxygen; Fluid Therapy	Device: Protoporphyrin IX - Triplet State Lifetime Technique

Detailed Description:

Evidence is increasing that there is no clear parameter for tissue oxygenation in critically ill septic patients to guide resuscitation. New studies have shown the potential of protoporphyrin IX-triple state lifetime technique to measure mitochondrial oxygenation tension (mitoPO2) in vivo, which possibly is an early indicator of oxygen disbalance in the cell and therefore a physiological trigger for fluid therapy.

Objectives: 1. To describe mitoPO2 measurements in patients with sepsis who are about to receive fluid therapy 2. To describe the effects of fluid therapy and the associated change in mitoPO2 and change in other physiologic measures of tissue oxygenation and oxygen balance 3.To describe the association between mitoPO2 and vital organ (dis)functions and change of SOFA (Sequential organ failure assessment) score after 24hrs 5. To describe the microcirculatory, cellular and mitochondrial function during the first 24 hours of septic patients.

Study population: critically ill patients with sepsis which are admitted to the intensive care unit through the emergency department or hospital ward and in whom fluid therapy (crystalloid, albumin and red cell transfusion) is planned.

Main study endpoints

Primary endpoint: Change in mitoPO2 after fluid therapy. This will be compared to traditional parameters used to measure oxygenation and oxygen balance

Secondary endpoints:

• Association of mitoPO2 trend with separate (ischemic) organ (dis)function. The SOFA score after 24 hours will also be assessed.
• Safety of mitoPO2 measurements in critically ill septic patients.
• Description of the association of sepsis with microcirculatory function, cellular function and mitochondrial function.
• Description of the association between mitoPO2 change and clinical outcomes , like length of stay(both ICU and in-hospital) and mortality (both ICU and in-hospital).

Study Design

• Study Type: Observational
• Estimated Enrollment: 100 participants
• Observational Model: Cohort
• Time Perspective: Prospective
• Official Title: Insufficient Oxygenation in Septic Patients
• Actual Study Start Date: February 13, 2019
• Estimated Primary Completion Date: December 30, 2021
• Estimated Study Completion Date: December 30, 2021

Groups and Cohorts

Group/Cohort	Intervention/treatment
Critically ill septic patients; Cohort: patients admitted via the emergency department or hospital ward to the intensive care unit of Leiden University Medical Center with the diagnosis sepsis or septic shock, who receive fluid therapy (either colloid, crystalloid and/or red blood cell) in their first day of admission to the ICU.	Device: Protoporphyrin IX - Triplet State Lifetime Technique; Protoporphyrin IX - Triplet State Lifetime Technique is a way to measure mitochondrial oxygen tension in a non-invasive way at bedside.

Outcome Measures

Primary Outcome Measures :

1. Change of mitoPO2 during first 24 hours of a septic patient [ Time Frame: 24 hours ]
   The primary endpoint is the change of mitoPO2(mitochondrial oxygenation) before and after fluid therapy in patients with sepsis. This will be compared to traditional parameters used to measure tissue oxygenation and oxygen balance (central venous oxygen saturation, mean arterial pressure and lactate).

Secondary Outcome Measures :

1. SOFA (sequential organ failure assessment) score after 24 hours [ Time Frame: 24 hours ]
   The association of mitoPO2 change in 24 hours with the Sequential Organ Failure Assessment score after 24 hours will be assessed. With the help of this information, more insight can be given in how much information the cutaneous mitoPO2 measurement gives about the organs separately and together.
2. Organ (dis)function [ Time Frame: 24 hours ]
   To describe the association between mitoPO2 change and separate organ functions.
3. Validation of mitoPO2 measurement with blood based biomarkers of cellular function [ Time Frame: 24 hours ]
   Cellular function will be assessed with blood-based biomarkers mitochondrial membrane potential (MMP), presence of cellular reactive oxygen species (ROS) molecules and glutathione (GSH) activity. Mitochondrial function will be assessed with mitoPO2 measurements.
4. Safety (incidence of adverse and serious adverse events) [ Time Frame: 24 hours ]
   The adverse and serious adverse events of the mitoPO2 measurements will be assessed.
5. Length of ICU stay [ Time Frame: 3 months ]
   Association of mitoPO2 change and length of intensive care unit-stay.
6. Length of hospital stay [ Time Frame: 3 months ]
   Association of mitoPO2 change and length of hospital stay.
7. ICU mortality [ Time Frame: 3 months ]
   Association of mitoPO2 change and intensive care unit mortality.
8. In-hospital mortality [ Time Frame: 3 months ]
   Association of mitoPO2 change and in-hospital mortality.

Biospecimen Retention:   Samples Without DNA

Blood samples will be taken for measurement of: creatinine, hemoglobin, lactate, central venous oxygen saturation, arterial saturation, arterial oxygen tension, venous oxygen tension, central venous-to-arterial carbon dioxide partial pressure difference. Furthermore, blood based cellular function will be assessed (presence of reactive oxygen species molecules, mitochondrial membrane potential and glutathione activity).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No
• Sampling Method: Non-Probability Sample

Study Population

Patients in the emergency department or hospital ward admitted to the Intensive Care Unit of the Leiden University Medical Center with (the suspicion of) sepsis will be the source population of the study. Leiden Univesity Medical Center is an academic hospital.

Septic patients are identified as specified in the Dutch protocol of sepsis identification and management in the emergency department. It consists of having clinical suspicion of sepsis in combination with the at least 2 of the following symptoms: ≥ 20 breaths per minute, heart frequency > 90 beats per minute, leukocytes > 12x109 or leukocytes < 4x10^9, and/or temperature > 38 °C or <36 °C

Criteria

Inclusion Criteria:

• Age of patient is at least 18 years
• Patients diagnosed with sepsis in the emergency department or hospital ward
• Patients are admitted to the ICU via the hospital ward or emergency department
• Informed consent is given either by the patient or if the patient is too ill to give informed consent, by his or her legal representative.
• Patients have an arterial catheter in situ, since blood samples will be taken for the study. Most patients admitted to the ICU have an arterial catheter in place since it is part of standard care.

Exclusion Criteria:

• Patients younger than 18 years
• Patients with sepsis discharged after emergency department visit
• Patients admitted to a hospital ward other than the ICU after emergency department visit
• Patients who cannot give informed consent themselves and without a legal representative will be excluded since no informed consent can be obtained
• Patients known with porphyria and/or photodermatosis will be excluded, since the risk of phototoxicity
• Patients with hypersensitivity to the active substance or to the plaster material of ALA (5-aminolevulinic acid)
• Pregnant or breast feeding women since there is no adequate data form the use of ALA in pregnant or breast feeding women
• Insufficient comprehensibility of the Dutch language

Contacts and Locations

Contacts

Contact: Meryem Baysan, MD; +31715297274; m.baysan@lumc.nl

Contact: Johanna G van der Bom, MD, PhD; +31715268871; J.G.van_der_Bom@lumc.nl

Locations

Netherlands

Leiden University Medical Center; Recruiting

Leiden, Netherlands, 2333 ZA

Contact: Meryem Baysan, MD +31715297274 m.baysan@lumc.nl

Sponsors and Collaborators

Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

Investigators

• Principal Investigator: Johanna G van der Bom, MD, PhD; Leiden University Medical Center and Sanquin Research Leiden
• Principal Investigator: M S Arbous, MD, PhD; Leiden University Medical Center

More Information

• Responsible Party: Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research
• ClinicalTrials.gov Identifier: NCT03842722
• Other Study ID Numbers: NL64824.058.18
• First Posted: February 15, 2019
• Last Update Posted: March 30, 2021
• Last Verified: March 2021

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:

Protoporphyrin IX; Photosensitizing Agents; Dermatologic Agents